A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer Disease

Immunotherapy has the potential to provide a possible treatment therapy to prevent or delay Alzheimer Disease. In a clinical trial (AN1792) in which patients received this immunotherapy and received active Aβ1–42 peptide immunizations, treatment was stopped when 6% of patients showed signs of mening...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Lambracht-Washington, Doris, B-X, Qu, Fu, Min, Larry Anderson, LD, Eagar, Todd N., Stüve, Olaf, Rosenberg, Roger N.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4084825/
https://ncbi.nlm.nih.gov/pubmed/23036592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jneuroim.2012.09.008
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller